The global fight against tuberculosis (TB) is gaining momentum with several promising vaccine candidates advancing through clinical trials. As of August 2024, the World Health Organization reports that 15 vaccine candidates are in clinical trials, with six having reached the critical Phase 3 stage. These developments are crucial in addressing the persistent challenge of TB, particularly in the face of rising antimicrobial resistance.
M72/AS01E: A Frontrunner in the TB Vaccine Race
Among the various candidates, the M72/AS01E (M72) vaccine has emerged as a prominent contender. This vaccine, supported by significant funding from the Bill & Melinda Gates Foundation and Wellcome, commenced Phase 3 trials earlier this year. The trial is designed to enroll approximately 20,000 participants, including individuals already infected with TB, to rigorously evaluate its efficacy and safety profile.
The M72 vaccine represents a significant advancement in TB prevention. The ongoing Phase 3 trial will provide critical data on its ability to prevent the progression of TB infection to active disease, a key factor in reducing the global TB burden.
The Urgent Need for New TB Vaccines
Elisabeth Mahase notes the critical importance of new vaccines in controlling TB, often referred to as the "disease of deprivation," and in combating antimicrobial resistance. The development of effective TB vaccines is essential for achieving global TB control and reducing the impact of this devastating disease, especially in vulnerable populations.
